Chronic Lymphocytic Leukemia (CLL)VeRVeNCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
An observational study of Chronic Lymphocytic Leukemia (CLL), run by AbbVie at 74 sites in 3 countries.
Trial summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Lymphocytic Leukemia (CLL)
- How many people
- 500 participants
- Where
- 74 sitesin 3 countries
- Study dates
- 4 Dec 2017to Dec 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with chronic lymphocytic leukemia (CLL) administering venetoclax per the local label.
Who may be able to join
- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Who cannot join
- None
Trial locations and contacts
74 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
Stefan Lorenz contact
74 sites in 3 countries
Germany61 sites, 4 recruiting
- Completed
MVZ am Klinikum Aschaffenburg Onkologie /ID# 201548
Aschaffenburg, Bavaria, 63739
- Completed
Studienzentrum Aschaffenburg /ID# 204125
Aschaffenburg, Bavaria, 63739
- Completed
Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 200950
Augsburg, Bavaria, 86150
- Completed
Praxis Dr. Kreher /ID# 202604
Bad Liebenwerda, Brandenburg, 04924
- Completed
Caritas-Krankenhaus gGmbH /ID# 243212
Bad Mergentheim, 97980
- Completed
Drs. Tanzer, Chirca, Stoeberl /ID# 202613
Bad Reichenhall, Bavaria, 83435
- Completed
MVZ Klinikum Mittelbaden GmbH /ID# 206207
Baden-Baden, 76532
- Completed
Praxis für Hämatologie und Onkologie /ID# 241763
Berlin, 10117
- Completed
Onkologische Schwerpunktpraxis /ID# 200953
Berlin, 10707
- Completed
Praxis am Volkspark /ID# 243195
Berlin, 10715
- Completed
Onkologie am Segelfliegerdamm /ID# 202603
Berlin, 12487
- Completed
Ambulantes Tumorzentrum Bremerhaven /ID# 224353
Bremerhaven, Free Hanseatic City of Bremen, 27576
- Completed
Pioh Dres. Draube & Partner /ID# 239507
Cologne, 50674
- Recruiting
Donauisar Klinikum Deggendorf /ID# 289012
Deggendorf, Bavaria, 94469
- Completed
Onkozentrum Dresden /ID# 202599
Dresden, Saxony, 01127
- Completed
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 201532
Dresden, Saxony, 01307
- Completed
Praxis Dres. Prange-Krex/Mohm /ID# 210049
Dresden, 01307
- Completed
St. Georg Klinikum Eisenach gemeinnützige GmbH (GKE) /ID# 250200
Eisenach, 99817
- Completed
Internistische Schwerpunktpraxen, Erlangen /ID# 200949
Erlangen, Bavaria, 91052
- Completed
Praxis Dres. Kiehl/Stein /ID# 210052
Frankfurt (Oder), Brandenburg, 15236
- Completed
Centrum fuer Haematologie und Onkologie Bethanien /ID# 206701
Frankfurt am Main, Hesse, 60389
- Completed
MVZ Dres. Cordes & Partner /ID# 202598
Frankfurt am Main, Hesse, 60596
- Completed
Klinikum Frankfurt Hoechst /ID# 210048
Frankfurt am Main, Hesse, 65929
- Recruiting
Varisano Klinikum Frankfurt Hoechst /ID# 288028
Frankfurt am Main, Hesse, 65929
- Completed
Praxis fuer interdisziplinaere Onkolologie und Haematologie /ID# 206999
Freiburg im Breisgau, 79110
- Completed
Onkologische Kooperation Harz /ID# 201550
Goslar, Lower Saxony, 38642
- Completed
MVZ Onkologie GmbH /ID# 212376
Hagen, 58095
- Completed
Evidia MVZ III Oncology Halle /ID# 218354
Halle, Saxony-Anhalt, 06110
- Completed
OncoResearch Lerchenfeld GmbH /ID# 205237
Hamburg, 22081
- Completed
Onkologische Gemeinschaftspraxis /ID# 205239
Hamburg, 22767
- Completed
Evangelisches Krankenhaus Hamm /ID# 206703
Hamm, 59063
- Recruiting
Onkologische Schwerpunktpraxis Hanau /ID# 287948
Hanau, Hesse, 63450
- Completed
OAZ Hannover /ID# 201538
Hanover, Lower Saxony, 30171
- Completed
Studienzentrum am Raschplatz /ID# 250180
Hanover, 30161
- Completed
Studienbüro Kamal und Dorn GBR /ID# 234105
Hanover, 30625
- Completed
Onkologie Hof /ID# 201531
Hof, Bavaria, 95028
- Completed
Klinikum Idar-Oberstein GmbH /ID# 210046
Idar-Oberstein, 55743
- Completed
Hämatologie und Onkologie /ID# 205247
Kaiserslautern, Rhineland-Palatinate, 67655
- Completed
Praxis Dres. Tebbe/Mayer /ID# 206730
Kassel, Hesse, 34125
- Completed
Praxis Dr. Stauch /ID# 202611
Kronach, Bavaria, 96317
- Completed
VK&K Studien GbR /ID# 202614
Landshut, Bavaria, 84036
- Completed
Praxis Fuchs/Koehler /ID# 243215
Langenhessen, 63225
- Completed
Luebecker Oncology Practice /ID# 200952
Lübeck, Schleswig-Holstein, 23562
- Recruiting
Gemeinschaftspraxis fuer Haematologie und Onkologie /ID# 281328
Magdeburg, 39104
- Completed
Haemato-Onkologie /ID# 205236
Munich, Bavaria, 81241
- Completed
Stauferklinikum Schwaebisch Gmuend /ID# 201518
Mutlangen, Baden-Wurttemberg, 73557
- Completed
Friedrich-Ebert-Krankenhaus GmbH /ID# 206206
Neumünster, Schleswig-Holstein, 24534
- Completed
Praxis Dr. Klaproth/Cura /ID# 216413
Neunkirchen, Saarland, 66538
- Completed
Praxis Dres. Plewe/Losem /ID# 202606
Neuss, North Rhine-Westphalia, 41462
- Completed
Onkolologische Praxis Oldenburg /ID# 202607
Oldenburg, Lower Saxony, 26121
- Completed
MVZ der Paracelsus-Klinik /ID# 201541
Osnabrück, Lower Saxony, 49076
- Completed
Bruederkrankenhaus St. Josef Paderborn /ID# 202600
Paderborn, 33098
- Completed
Onkologische Praxis GbR /ID# 206705
Porta Westfalica, 32457
- Completed
MVZ f. Blut- u.Krebserkrankungen /ID# 206704
Potsdam, Brandenburg, 14467
- Completed
Praxis Dres. Krober/Stosiek /ID# 206729
Regensburg, State of Berlin, 93053
- Completed
Praxis Dres. Decker/Lakner/Leithäuser /ID# 206208
Rostock, 18057
- Completed
Diakonieklinikum Schwaebisch Hall /ID# 206205
Schwäbisch Hall, 74523
- Completed
MVZ am Schlossgarten GmbH /ID# 210043
Schwetzingen, 68723
- Completed
Onkologische Praxis /ID# 201545
Stuttgart, Baden-Wurttemberg, 70174
- Completed
Schwarzwald-Baar-Klinikum /ID# 208176
Villingen-Schwenningen, Baden-Wurttemberg, 78052
- Completed
Med. Studiengesellschaft Nord West GmbH /ID# 201535
Westerstede, Lower Saxony, 26655
Switzerland9 sites, 1 recruiting
- Completed
Kantonsspital Aarau AG /ID# 210034
Aarau, Canton of Aargau, 5001
- Completed
EOC Ospedale Regionale di Bellinzona e Valli /ID# 208782
Bellinzona, Canton Ticino, 6500
- Completed
Inselspital, Universitaetsspital Bern /ID# 210031
Bern, 3010
- Completed
Luzerner Kantonsspital /ID# 210029
Lucerne, Canton of Lucerne, 6000
- Completed
Kantonsspital Münsterlingen /ID# 210035
Münsterlingen, Thurgau, 8596
- Recruiting
Réseau Hospitalier Neuchâtelois /ID# 227865
Neuchâtel, Canton of Neuchâtel, 2000
- Completed
Kantonsspital St. Gallen /ID# 223037
Sankt Gallen, Canton of St. Gallen, 9007
- Completed
Spital Thun /ID# 233714
Thun, Canton of Bern, 3600
- Completed
KSW Kantonsspital Winterthur /ID# 211068
Winterthur, Canton of Zurich, 8400
Austria4 sites
- Completed
Medizinische Universitaet Graz /ID# 221155
Graz, Styria, 8010
- Active, not recruiting
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
Salzburg, 5020
- Completed
Universitaetsklinikum St. Poelten /ID# 221152
Sankt Pölten, Lower Austria, 3100
- Completed
Hanusch Krankenhaus /ID# 221151
Vienna, 1140
About this study
Official title: Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Keywords
- Chronic Lymphocytic Leukemia (CLL), Cancer, Leukemia, venetoclax, rituximab, obinutuzumab, ABT-199, venclexta, venclyxto
- Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Leukemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants Receiving Venetoclax | Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax. | |
| Participants Receiving Venetoclax + Rituximab | Participants with CLL receiving venetoclax in combination with rituximab. | |
| Participants Receiving Venetoclax + Obinutuzumab | Participants with CLL receiving venetoclax in combination with obinutuzumab. | |
| Participants Receiving Venetoclax + Ibrutinib | Participants with CLL receiving venetoclax in combination with ibrutinib. | |
| Participants Receiving Venetoclax + Acalabrutinib | Participants with CLL receiving venetoclax in combination with acalabrutinib. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving Best Overall Response Rate (ORR)
ORR is defined as the percentage of participants achieving partial response (PR) and complete response with incomplete regeneration of bone marrow (CRi) and complete response (CR) according to physician's assessment to therapy with venetoclax.
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2017
- Study start4 Dec 2017
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Lymphocytic Leukemia (CLL)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03342144
- Sponsor's protocol ID
- P17-132
- Acronym
- VeRVe
- Status last verified
- Oct 2026
- First submitted
- 10 Nov 2017
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, Hulsenbeck J, Famulla K, Nosslinger T, Rossi D. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Ann Hematol. 2024 Jun;103(6):2013-2020. doi: 10.1007/s00277-024-05638-7. Epub 2024 Feb 29.
PubMed 38421404